etoposide has been researched along with Esophagitis in 34 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (2.94) | 18.7374 |
1990's | 8 (23.53) | 18.2507 |
2000's | 13 (38.24) | 29.6817 |
2010's | 11 (32.35) | 24.3611 |
2020's | 1 (2.94) | 2.80 |
Authors | Studies |
---|---|
Chen, X; Geng, Y; Hu, Y; Jiang, W; Li, Q; Lu, B; Luo, D; Ma, Z; Ouyang, W; Su, S; Wang, M; Wu, B; Yang, W | 1 |
Appel, W; Ashcroft, L; Barlesi, F; Bezjak, A; Bhatnagar, A; Blackhall, F; Cardenal, F; Faivre-Finn, C; Fournel, P; Harden, S; Le Pechoux, C; Lorigan, P; McMenemin, R; Mohammed, N; O'Brien, M; Pantarotto, J; Snee, M; Surmont, V; Van Meerbeeck, JP; Woll, PJ | 1 |
Aggarwal, C; Berman, AT; Cohen, RB; Evans, TL; Langer, C; Levin, WP; Lin, L; Rengan, R; Rwigema, JM; Simone, CB; Verma, V | 1 |
Li, H; Sun, X; Xie, P; Xing, L; Yu, J; Zhang, X; Zhao, H; Zhu, W | 1 |
Batus, M; Bonomi, P; Dandekar, VK; Fidler, MJ; Kiel, K; Sher, DJ; Young, J | 1 |
Algara, M; Fernández-Velilla, E; Foro, P; Lacruz, M; López, JL; Lozano, J; Membrive, I; Quera, J; Reig, A; Rodríguez, N; Sanz, X | 1 |
Bao, Y; Chen, M; Chen, YY; Gao, JM; He, H; Hu, X; Liu, Y; Poudel, S; Sun, ZW; Wang, WH; Wang, Y; Zhang, L; Zhuang, TT | 1 |
Aguero, EG; Fortney, JA; Garrett-Mayer, E; Sharma, AK; Sherman, CA; Shirai, K; Wahlquist, AE; Watkins, JM | 1 |
Crowley, JJ; Gandara, DR; Gaspar, LE; Goldberg, Z; Lara, PN; Le, QT; Moon, J; Moore, DF; Redman, M; Williamson, SK | 1 |
Jeremić, B; Miličić, B; Milisavljevic, S | 1 |
Byhardt, R; Curran, WJ; Paulus, R; Werner-Wasik, M | 1 |
Bi, N; Cao, J; Li, J; Li, W; Liang, J; Lv, J; Ou, G; Ren, H; Wang, L; Wu, S; Zhang, X; Zhou, Z | 1 |
Bradley, JD; Choy, H; Curran, WJ; Ettinger, DS; Glisson, BS; Komaki, R; Langer, CJ; Paulus, R; Sause, WT; Videtic, GM | 1 |
Dong, XJ; Li, LY; Wang, MZ; Xia, Y; Zhang, L; Zhang, XT; Zhao, J; Zhong, W | 1 |
Ansari, RH; Atkins, JN; Bogart, JA; Green, MR; Hodgson, LD; Kelley, MJ; Pang, H; Vokes, EE | 1 |
Bootsma, G; Borger, J; De Ruysscher, D; Dingemans, AM; Geraedts, W; Lambin, P; Lunde, R; Pitz, C; Reymen, B; van Baardwijk, A; Van Loon, J; Wanders, R | 1 |
Acquati, M; Ardizzoia, A; Casartelli, C; Fagnani, D; Fusco, O; Giordano, M; Malugani, F; Quattrone, A; Scanni, A; Tagliabue, P; Vergani, C; Visini, M | 1 |
Crowley, JJ; Dakhil, SR; Edelman, MJ; Gandara, DR; Gaspar, LE; Le, QT; McCoy, J; Ryu, J; Sides, SD; Williamson, S | 1 |
Byhardt, RW; Ettinger, DS; Glisson, BS; Komaki, R; Movsas, B; Sandler, AB; Suh, J; Swann, RS | 1 |
Bozóky, G; Gábor, G; Góhér, I; Lengyel, M; Mohos, A; Ruby, E | 1 |
Arnaiz Fernández, MD; Cardenal Alemany, F; Guedea Edo, F; Jeremic, B; Lucas Calduch, A; Montes Borinaga, A; Navarro Pérez, V; San José Maderuelo, S; Serrano Bermúdez, G | 1 |
Aisner, J; Van Echo, DA; Wiernik, PH | 1 |
Bullorsky, EO; Ceresetto, JM; Pest, P; Peters, RA; Shanley, CM; Stemmelin, GR | 1 |
Greco, FA; Hainsworth, JD; Stroup, SL | 1 |
Albrecht, H; Berger, J; Meigel, W; Plettenberg, A; Stellbrink, HJ; Stoehr, A; van Dyk, U | 1 |
Gandara, DR; Lau, DH; Rosenthal, SA; Ryu, JK | 1 |
Hirota, S; Hishikawa, Y; Honda, K; Kono, K; Obayasi, K; Soejima, T; Takada, Y; Watanabe, H | 1 |
Bernard, S; Carey, RW; Choi, NC; Chung, CT; Green, M; Herndon, JE; Leone, L; Rosenman, J; Seagren, S | 1 |
Alvarez Román, MT; Canales Albendea, MA; Hernández Navarro, F; Villanueva Pavón, R | 1 |
Andras, EJ; Byhardt, RW; Graham, ML; Roach, M; Scott, C; Smith, C; Werner-Wasik, M | 1 |
Fueki, N; Hoshino, H; Ishihara, S; Kobayashi, G; Makimoto, T; Minato, K; Mori, M; Naruse, I; Nomoto, T; Saito, R; Sato, K; Sunaga, N; Takei, Y; Takise, A; Tsuchiya, S; Watanabe, S | 1 |
Glisson, B; Komaki, R; Movsas, B; Scott, C; Wagner, H | 1 |
Ahn, YC; Han, J; Huh, SJ; Kim, DY; Kim, HJ; Kim, J; Kim, KM; Kwon, J; Lee, JE; Lee, KS; Lim, DH; Noh, YJ; Park, K; Shim, YM | 1 |
Allen, P; Cox, JD; Fossella, FV; Glisson, B; Herbst, R; Hong, WK; Kaplan, B; Kelly, JF; Khuri, F; Komaki, R; Kurie, J; Lee, JS; Liao, Z; Milas, L; Papadimitrakopoulou, V; Pisters, K; Ro, J; Stevens, CW; Thames, HD; Zinner, R | 1 |
17 trial(s) available for etoposide and Esophagitis
Article | Year |
---|---|
Preliminary results of randomized phase II study of etoposide plus lobaplatin or etoposide plus cisplatin with concurrent thoracic radiotherapy in the treatment of limited-stage small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophagitis; Etoposide; Humans; Lung Neoplasms; Radiation Pneumonitis; Small Cell Lung Carcinoma | 2023 |
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Follow-Up Studies; Humans; Intention to Treat Analysis; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiation Pneumonitis; Small Cell Lung Carcinoma; Survival Rate | 2017 |
A phase I study of concurrent chemotherapy and thoracic radiotherapy with oral epigallocatechin-3-gallate protection in patients with locally advanced stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Catechin; Chemoradiotherapy; Cisplatin; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage | 2014 |
Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma; Survival Rate; Tirapazamine; Triazines | 2009 |
Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonia; Retrospective Studies; Treatment Outcome | 2012 |
Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neutropenia; Paclitaxel; Radiation Pneumonitis; Treatment Outcome | 2012 |
Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical Protocols; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Cisplatin; Confidence Intervals; Dehydration; Disease-Free Survival; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Small Cell Lung Carcinoma | 2013 |
Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian phase II study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophagitis; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes; Premedication; Remission Induction; Stomatitis; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tirapazamine; Triazines; Vomiting | 2004 |
Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Endpoint Determination; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Radiotherapy Dosage; Survival Rate; Vomiting | 2005 |
[The effect of chemo-radiotherapy on the remission and survival in patients with limited stage small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonia; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
Paclitaxel by 1-hour infusion in combination chemotherapy of stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Esophagitis; Etoposide; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Leukopenia; Lung Neoplasms; Neoplasm Staging; Neutropenia; Paclitaxel; Radiotherapy; Remission Induction | 1995 |
Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 1998 |
A phase II study of combined chemoradiotherapy for limited disease-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Doxorubicin; Esophagitis; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2000 |
Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Treatment Outcome | 2000 |
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Injuries; Radiation Pneumonitis; Radiation-Protective Agents | 2002 |
17 other study(ies) available for etoposide and Esophagitis
Article | Year |
---|---|
Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dose Fractionation, Radiation; Esophagitis; Esophagus; Etoposide; Female; Heart; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Organs at Risk; Prospective Studies; Proton Therapy; Radiation Pneumonitis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Small Cell Lung Carcinoma; Spinal Cord; Treatment Outcome | 2017 |
Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Chest Pain; Cohort Studies; Cough; Dyspnea; Esophagitis; Etoposide; Female; Hemoptysis; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Pemetrexed; Radiation Injuries; Radiation Pneumonitis; Retrospective Studies; Treatment Outcome | 2015 |
Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; ROC Curve; Small Cell Lung Carcinoma; Tumor Burden; Vinblastine; Vinorelbine | 2009 |
[Efficacy of chemotherapy combined hyperfractionated accelerated radiotherapy on limited small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Follow-Up Studies; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiation Pneumonitis; Radiotherapy, High-Energy; Remission Induction; Small Cell Lung Carcinoma; Survival Rate | 2008 |
Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma | 2009 |
Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Etoposide; Follow-Up Studies; Humans; Lung Neoplasms; Neoplasm Staging; Pneumonia; Radiation Injuries; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine | 2011 |
[Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Myelopoiesis; Radiation Pneumonitis; Radiotherapy, Conformal; Remission Induction; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Chemoradiotherapy; Cranial Irradiation; Disease Progression; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Irradiation; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Radionuclide Imaging; Radiotherapy Dosage; Severity of Illness Index; Small Cell Lung Carcinoma; Tumor Burden | 2013 |
[Combined radiochemotherapy in localised small-cell lung cancer. Concurrent treatment protocols?].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; Esophagitis; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Radiation Pneumonitis; Radiotherapy; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2005 |
High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.
Topics: Adult; Antineoplastic Agents; Child; Drug Evaluation; Esophagitis; Etoposide; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Nausea; Pilot Projects; Podophyllotoxin; Vomiting | 1980 |
Severe esophageal stricture after autologous bone marrow transplant.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Esophageal Stenosis; Esophagitis; Etoposide; Fatal Outcome; Female; Humans; Immunocompromised Host; Leukemia, Myeloid; Melphalan; Middle Aged | 1995 |
Increased risk for opportunistic infections during chemotherapy in HIV-infected patients with Kaposi's sarcoma.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Candidiasis; Case-Control Studies; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Doxorubicin; Esophagitis; Etoposide; Follow-Up Studies; HIV Infections; Humans; Male; Pneumonia, Pneumocystis; Prognosis; Prospective Studies; Risk Factors; Sarcoma, Kaposi; Skin Neoplasms; Vinblastine; Vincristine | 1997 |
Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Esophagitis; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pilot Projects | 1997 |
[Endoscopic findings of esophagitis in concurrent chemo-radiotherapy for lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Esophagitis; Esophagoscopy; Etoposide; Humans; Lung Neoplasms; Middle Aged; Mitomycin; Radiation Injuries; Radiotherapy; Vindesine | 1998 |
[Severe esophageal stenosis secondary to the administration of chemotherapy in a patient with acute myeloblastic leukemia].
Topics: Anti-Infective Agents; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dilatation; Esophageal Stenosis; Esophagitis; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Recurrence; Remission Induction; Transplantation Conditioning; Ulcer | 1999 |
Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Survival Analysis; Vinblastine | 1999 |
Preoperative concurrent chemoradiotherapy for stage IIIA non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Esophagitis; Etoposide; Female; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Preoperative Care; Prospective Studies; Radiation Injuries; Radioisotope Teletherapy; Radiotherapy, Adjuvant; Survival Analysis; Survival Rate; Treatment Outcome | 2001 |